Ocuphire Pharma Dirección
Dirección controles de criterios 1/4
El CEO de Ocuphire Pharma's es George Magrath , nombrado en Nov 2023, tiene una permanencia de menos de un año. compensación anual total es $3.15M, compuesta por 3% salario y 97% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.098% de las acciones de la empresa, por valor de $49.75K. La antigüedad media del equipo directivo y de la junta directiva es de 0.5 años y 3.5 años, respectivamente.
Información clave
George Magrath
Chief Executive Officer (CEO)
US$3.1m
Compensación total
| Porcentaje del salario del CEO | 3.0% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 3.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch
May 02
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11Ocuphire drops 11% on $15M at-the money direct offering
Jun 04Ocuphire Pharma EPS beats by $0.36
May 07Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?
Feb 08Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition
Jan 06Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances
Jan 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$3m | US$96k | -US$10m |
Compensación vs. Mercado: La compensación total de George($USD3.15M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD663.90K).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de George con los resultados de la empresa.
CEO
George Magrath (39 yo)
less than a year
Permanencia
US$3,146,518
Compensación
Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Ocuphire Pharma, Inc. since November 1, 2023. He was an Analyst at Edison Investment Research Limited since 2015. He covered the healthcare sect...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.15m | 0.098% $ 42.5k | |
| Senior Vice President of Corporate Development & Secretary | no data | US$789.92k | 0.42% $ 183.2k | |
| Senior Vice President of Finance | no data | US$789.92k | 0.030% $ 13.1k | |
| Chief Financial Officer | less than a year | sin datos | 0.59% $ 255.0k | |
| Chief Operating Officer | less than a year | sin datos | 0.0078% $ 3.4k | |
| Chief Scientific & Development Officer | less than a year | sin datos | sin datos | |
| Head of Market Development & Commercialization | 2.3yrs | sin datos | sin datos | |
| Director & Corporate Controller | no data | sin datos | sin datos |
0.5yrs
Permanencia media
43.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de OCUP no se considera experimentado ( 0.4 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.15m | 0.098% $ 42.5k | |
| Independent Director | 3.5yrs | US$154.81k | 0.31% $ 135.9k | |
| Chief Medical Advisor | 6.3yrs | US$662.10k | 0.24% $ 104.3k | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.5yrs | US$1.35m | 0.44% $ 192.1k | |
| Member of Medical Advisory Board | 4.3yrs | sin datos | sin datos | |
| Independent Chairman | 3.5yrs | US$174.62k | 0.097% $ 42.4k | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Lead Independent Director | 3.5yrs | US$149.56k | 0.14% $ 61.6k | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos |
3.5yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de OCUP se considera experimentada (3.4 años de antigüedad promedio).